Jushi Q2 Revenue Hits $71.3M, Wholesale Record $9.4M; Virginia Adult-Use on Horizon
JUSHF is trading near its 52-week low of $0.35 (10% above the low).
Summary
Jushi Holdings reported Q2 2026 revenue of $71.3 million, a 10% year-over-year increase, with wholesale revenue surging 68% to a record $9.4 million. The company also highlighted the elimination of Section 280E and Virginia's upcoming adult-use market as key catalysts.
Key Events · Earnings and Guidance · JUSHF
-
Q2 Revenue Up 10% to $71.3M
Revenue grew 10% year-over-year to $71.3 million, driven by a 4% increase in retail revenue to $61.9 million and a 68% surge in wholesale revenue to a record $9.4 million.
-
Wholesale Revenue Hits All-Time High
Wholesale revenue reached $9.4 million, up 68% from Q2 2025, fueled by higher production volumes, improved product quality, and expanded distribution across multiple states.
-
Net Loss Narrows to $7.3M
Net loss improved to $7.3 million from $12.3 million a year ago, helped by a $6.4 million discrete tax benefit from the elimination of Section 280E following federal rescheduling of medical marijuana.
-
Virginia Adult-Use Market Set for July 2027
Virginia enacted legislation establishing a regulated adult-use cannabis market, with sales commencing July 1, 2027. Jushi is advancing cultivation and processing investments to capitalize on this opportunity.
Analysis · JUSHF · Life Sciences
Jushi delivered a solid quarter with 10% revenue growth and a record wholesale performance, but the real story is the strategic tailwinds: federal rescheduling eliminated the 280E tax burden, unlocking a $6.4M benefit, and Virginia's adult-use legislation sets the stage for a major market expansion in mid-2027. Against a backdrop of a going-concern warning from the last 10-Q, the improved cash position and positive operating cash flow provide some breathing room, though the heavy debt load remains a risk.
At the time of this filing, JUSHF was trading at $0.39 on OTC in the Life Sciences sector, with a market capitalization of approximately $77M. The 52-week trading range was $0.35 to $0.98. This filing was assessed with positive market sentiment and an importance score of 7 out of 10.